A Meta-Analysis on the Efficacy and Safety of Bacterial Lysates in Chronic Obstructive Pulmonary Disease
BackgroundChronic obstructive pulmonary disease (COPD) is a common and frequently encountered disease of respiratory apparatus and is vulnerable to infection. Increasing studies reveal that bacterial lysates play an encouraging role in preventing exacerbations in these patients. We here investigated...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.877124/full |
| _version_ | 1828779249702535168 |
|---|---|
| author | Yongkang Huang Yongjian Pei Yajuan Qian Zhen Yao Chen Chen Juan Du Minhua Shi Tong Zhou |
| author_facet | Yongkang Huang Yongjian Pei Yajuan Qian Zhen Yao Chen Chen Juan Du Minhua Shi Tong Zhou |
| author_sort | Yongkang Huang |
| collection | DOAJ |
| description | BackgroundChronic obstructive pulmonary disease (COPD) is a common and frequently encountered disease of respiratory apparatus and is vulnerable to infection. Increasing studies reveal that bacterial lysates play an encouraging role in preventing exacerbations in these patients. We here investigated the efficacy and safety of bacterial lysates in COPD.MethodsWe performed systematic research on PubMed, EMBASE, the Cochrane Library (CENTRAL), and Web of Science by using the keywords and their synonyms for studies published before January 11, 2022. Two researchers screened the studies of literature independently according to the inclusion and exclusion criteria and extracted data from the included studies. Another two researchers assessed the risk of bias of each included using the Cochrane risk-of-bias tool. Meta-analysis was conducted using R (version 4.1.1, The R Foundation for Statistical Computing) and Review Manager (version 5.4.0, The Cochrane Collaboration).ResultsA total of 12 studies were included in this meta-analysis, and the pooled results showed that bacterial lysates were effective to reduce exacerbation rate (overall: relative risk [RR] = 0.83, 95% confidence interval [CI] 0.72–0.96; alkaline bacterial lysate subgroup [OM-85]: RR = 0.87, 95% CI 0.77–0.98; mechanical bacterial lysate subgroup [Ismigen]: RR = 0.70, 95% CI 0.41–1.20) and mean number of exacerbations (overall: MD = −0.42, 95% CI −0.75 to −0.08; alkaline bacterial lysate subgroup [OM-85]: MD = −0.72, 95% CI −1.35 to −0.09; mechanical bacterial lysate subgroup [Ismigen]: MD = −0.02, 95% CI −0.21 to 0.17). Bacterial lysates were also found beneficial in alleviating symptoms. The side effects were acceptable and slight.ConclusionBacterial lysates can benefit patients with COPD by reducing exacerbations and alleviating symptoms. OM-85 is the preferable product based on the existing evidence. Further studies are needed to validate these findings.Systematic Review Registration[www.crd.york.ac.uk/prospero/], identifier [CRD42022299420]. |
| first_indexed | 2024-12-11T16:57:58Z |
| format | Article |
| id | doaj.art-936b68cdc52e462ab953ac92c902f045 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-11T16:57:58Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-936b68cdc52e462ab953ac92c902f0452022-12-22T00:57:54ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-06-01910.3389/fmed.2022.877124877124A Meta-Analysis on the Efficacy and Safety of Bacterial Lysates in Chronic Obstructive Pulmonary DiseaseYongkang Huang0Yongjian Pei1Yajuan Qian2Zhen Yao3Chen Chen4Juan Du5Minhua Shi6Tong Zhou7Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, ChinaDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, ChinaDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, ChinaDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, ChinaDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, ChinaDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, ChinaDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, ChinaDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, ChinaBackgroundChronic obstructive pulmonary disease (COPD) is a common and frequently encountered disease of respiratory apparatus and is vulnerable to infection. Increasing studies reveal that bacterial lysates play an encouraging role in preventing exacerbations in these patients. We here investigated the efficacy and safety of bacterial lysates in COPD.MethodsWe performed systematic research on PubMed, EMBASE, the Cochrane Library (CENTRAL), and Web of Science by using the keywords and their synonyms for studies published before January 11, 2022. Two researchers screened the studies of literature independently according to the inclusion and exclusion criteria and extracted data from the included studies. Another two researchers assessed the risk of bias of each included using the Cochrane risk-of-bias tool. Meta-analysis was conducted using R (version 4.1.1, The R Foundation for Statistical Computing) and Review Manager (version 5.4.0, The Cochrane Collaboration).ResultsA total of 12 studies were included in this meta-analysis, and the pooled results showed that bacterial lysates were effective to reduce exacerbation rate (overall: relative risk [RR] = 0.83, 95% confidence interval [CI] 0.72–0.96; alkaline bacterial lysate subgroup [OM-85]: RR = 0.87, 95% CI 0.77–0.98; mechanical bacterial lysate subgroup [Ismigen]: RR = 0.70, 95% CI 0.41–1.20) and mean number of exacerbations (overall: MD = −0.42, 95% CI −0.75 to −0.08; alkaline bacterial lysate subgroup [OM-85]: MD = −0.72, 95% CI −1.35 to −0.09; mechanical bacterial lysate subgroup [Ismigen]: MD = −0.02, 95% CI −0.21 to 0.17). Bacterial lysates were also found beneficial in alleviating symptoms. The side effects were acceptable and slight.ConclusionBacterial lysates can benefit patients with COPD by reducing exacerbations and alleviating symptoms. OM-85 is the preferable product based on the existing evidence. Further studies are needed to validate these findings.Systematic Review Registration[www.crd.york.ac.uk/prospero/], identifier [CRD42022299420].https://www.frontiersin.org/articles/10.3389/fmed.2022.877124/fullchronic obstructive pulmonary diseasebacteria lysatesOM-85Ismigenefficacysafety |
| spellingShingle | Yongkang Huang Yongjian Pei Yajuan Qian Zhen Yao Chen Chen Juan Du Minhua Shi Tong Zhou A Meta-Analysis on the Efficacy and Safety of Bacterial Lysates in Chronic Obstructive Pulmonary Disease Frontiers in Medicine chronic obstructive pulmonary disease bacteria lysates OM-85 Ismigen efficacy safety |
| title | A Meta-Analysis on the Efficacy and Safety of Bacterial Lysates in Chronic Obstructive Pulmonary Disease |
| title_full | A Meta-Analysis on the Efficacy and Safety of Bacterial Lysates in Chronic Obstructive Pulmonary Disease |
| title_fullStr | A Meta-Analysis on the Efficacy and Safety of Bacterial Lysates in Chronic Obstructive Pulmonary Disease |
| title_full_unstemmed | A Meta-Analysis on the Efficacy and Safety of Bacterial Lysates in Chronic Obstructive Pulmonary Disease |
| title_short | A Meta-Analysis on the Efficacy and Safety of Bacterial Lysates in Chronic Obstructive Pulmonary Disease |
| title_sort | meta analysis on the efficacy and safety of bacterial lysates in chronic obstructive pulmonary disease |
| topic | chronic obstructive pulmonary disease bacteria lysates OM-85 Ismigen efficacy safety |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.877124/full |
| work_keys_str_mv | AT yongkanghuang ametaanalysisontheefficacyandsafetyofbacteriallysatesinchronicobstructivepulmonarydisease AT yongjianpei ametaanalysisontheefficacyandsafetyofbacteriallysatesinchronicobstructivepulmonarydisease AT yajuanqian ametaanalysisontheefficacyandsafetyofbacteriallysatesinchronicobstructivepulmonarydisease AT zhenyao ametaanalysisontheefficacyandsafetyofbacteriallysatesinchronicobstructivepulmonarydisease AT chenchen ametaanalysisontheefficacyandsafetyofbacteriallysatesinchronicobstructivepulmonarydisease AT juandu ametaanalysisontheefficacyandsafetyofbacteriallysatesinchronicobstructivepulmonarydisease AT minhuashi ametaanalysisontheefficacyandsafetyofbacteriallysatesinchronicobstructivepulmonarydisease AT tongzhou ametaanalysisontheefficacyandsafetyofbacteriallysatesinchronicobstructivepulmonarydisease AT yongkanghuang metaanalysisontheefficacyandsafetyofbacteriallysatesinchronicobstructivepulmonarydisease AT yongjianpei metaanalysisontheefficacyandsafetyofbacteriallysatesinchronicobstructivepulmonarydisease AT yajuanqian metaanalysisontheefficacyandsafetyofbacteriallysatesinchronicobstructivepulmonarydisease AT zhenyao metaanalysisontheefficacyandsafetyofbacteriallysatesinchronicobstructivepulmonarydisease AT chenchen metaanalysisontheefficacyandsafetyofbacteriallysatesinchronicobstructivepulmonarydisease AT juandu metaanalysisontheefficacyandsafetyofbacteriallysatesinchronicobstructivepulmonarydisease AT minhuashi metaanalysisontheefficacyandsafetyofbacteriallysatesinchronicobstructivepulmonarydisease AT tongzhou metaanalysisontheefficacyandsafetyofbacteriallysatesinchronicobstructivepulmonarydisease |